Blockchain Registration Transaction Record

Lantern Pharma to Unveil OMAI AI Growth Plan in Live Webinar

Lantern Pharma to present OMAI AI growth plan in live webinar today. CEO Panna Sharma covers market opportunity, platform capabilities, and roadmap.

The webinar will provide critical insights into how Lantern Pharma's Open-Medicine AI subsidiary plans to commercialize a multi-agentic AI platform for drug development, potentially accelerating the pace and reducing the cost of bringing new therapies to market. For investors, the session offers a rare look at the platform's economics, benchmarks, and partnership strategy, which could influence the company's valuation and competitive positioning in the rapidly evolving AI-driven biopharma landscape. As AI continues to transform oncology research, Lantern's progress with OMAI and its RADR platform may signal broader shifts in how precision medicines are discovered and developed, ultimately impacting patient access to targeted treatments.